Payment overview · 2025
General Payments
$200.52
10 reported records · 4 companies
Healthcare provider profile · identity verified
George Douglas Sagrera, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEW IBERIA, LA · NPI 1093772402
Verified facts
What the public records show
CMS Open Payments records show George Douglas Sagrera, MD received $200.52 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.68 | 35.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.94 | 30.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.84 | 18.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.06 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.52 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $71.68 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 516 | 88 |
| Omeprazole | Omeprazole | 367 | 74 |
| Alprazolam | Alprazolam | 309 | 37 |
| Metformin Hcl | Metformin Hcl | 302 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 64 |
| Tramadol Hcl | Tramadol Hcl | 263 | 36 |
| Lorazepam | Lorazepam | 215 | 31 |
| Simvastatin | Simvastatin | 212 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 205 | 56 |
| Naproxen | Naproxen | 191 | 39 |
| Meloxicam | Meloxicam | 183 | 36 |
| Furosemide | Furosemide | 166 | 36 |
| Allopurinol | Allopurinol | 165 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 153 | 34 |
| Glimepiride | Glimepiride | 149 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 144 | 55 |
| Prednisone | Prednisone | 143 | 46 |
| Clonazepam | Clonazepam | 140 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 29 |
| Cephalexin | Cephalexin | 133 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 27 |
| Lisinopril | Lisinopril | 130 | 34 |
| Trazodone Hcl | Trazodone Hcl | 127 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 125 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 21 |
| Sertraline Hcl | Sertraline Hcl | 112 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 14 |
| Meclizine Hcl | Meclizine Hcl | 96 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 14 |
| Celecoxib | Celecoxib | 91 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 16 |
| Temazepam | Temazepam | 80 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 19 |
| Eliquis | Apixaban | 77 | 11 |
| Azithromycin | Azithromycin | 74 | 52 |
| Cefdinir | Cefdinir | 72 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 17 |
| Estradiol | Estradiol | 70 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 26 |
| Ibuprofen | Ibuprofen | 68 | 19 |
| Potassium Chloride | Potassium Chloride | 68 | 14 |
| Losartan Potassium | Losartan Potassium | 66 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 16 |
| Carvedilol | Carvedilol | 62 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 17 |
| Bupropion Xl | Bupropion Hcl | 61 | suppressed |
| Diazepam | Diazepam | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 15 |
| Donepezil Hcl | Donepezil Hcl | 58 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | suppressed |
| Atenolol | Atenolol | 55 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 55 | 11 |
| Finasteride | Finasteride | 55 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Methotrexate | Methotrexate Sodium | 50 | suppressed |
| Jardiance | Empagliflozin | 49 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 15 |
| Phenobarbital | Phenobarbital | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 13 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Glipizide | Glipizide | 43 | 12 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 12 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 15 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 22 |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Glyburide | Glyburide | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Flurbiprofen | Flurbiprofen | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.52 · 10 records | Lilly USA, LLC | ELIQUIS, JARDIANCE, JOURNAVX, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error